Melbourne, May 28, 2010 (ABN Newswire) - Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.
Mesoblast was one of only two emerging market leaders in the healthcare sector that were showcased to around 150 targeted global investors. The conference featured only 15 companies, predominantly from the resources sector, with market capitalisations of up to A$1 billion.
Chief Executive, Professor Silviu Itescu, updated investors on Mesoblast's acquisition of its United States associate company, Angioblast Systems, its near term growth strategies and plans for early product revenues.
Background
Mesoblast Limited is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).
About Mesoblast Limited
Mesoblast Limited (ASX:MSB) (OTC ADR: MBLTY) is the world's leading developer of innovative biological products for the broad field of regenerative medicine.
Mesoblast's commercial strategy is based on its unique proprietary adult mesenchymal precursor cells.
The company's lead products will target cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.
Mesoblast and global biopharmaceutical company Cephalon Inc. have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.
Mesoblast Limited
){kind=link}